Supportive care with methylenedioxymethamphetamine (MDMA), according to researchers, has been shown to help people suffering from severe post-traumatic stress disorder (PTSD).The most recent study, which was first published in the journal Nature Medicine in May, was led by San Jose, author of the University of New York, San Francisco, California, and California’s non-profit MAPS (Interdisciplinary Association for Hallucinogens), and is a common co-existence. For 18 weeks, patients with severe PTSD, including the disease, are given MDMA, or “ecstasy,” three times in combination with manual therapy.
CALIFORNIA SCHOOL OFFICIALS WARN PARENTS ABOUT NEW ADDICTIVE DRUG SALES:
REPORTParticipants in the double-blind study were randomly assigned to receive either manual therapy with psychedelics or a placebo, as well as three preparatory sessions and nine integrated therapy sessions.A clinician-managed PTSD scale was used to assess PTSD symptoms, and the Sihan Disability Scale was used to assess dysfunction. Both were evaluated during the study’s baseline and two months after the last experimental session.
Suicidal thoughts and negative events were also monitored. The study enrolled 131 patients, 91 of whom were confirmed randomised in the United States, Canada, and Israel, 56 of whom were randomised to MDMA, and 44 of whom received placebo. The researchers discovered that each person had “significant and strong attenuation of PTSD symptoms and dysfunction.”
Furthermore, the researchers stated that MDMA “significantly reduced” depressive symptoms, did not increase the incidence of suicidal tendencies during the study, and did not induce adverse events associated with possible abuse.
Furthermore, there was no discernible effect of previous antidepressant use on treatment trial efficacy, and there was no clear relationship between the duration or initiation of PTSD diagnosis and treatment efficacy.”Poisoning is a modern plague,” says Anna Lembke.
This has a long shelf life.”These findings show that MDMA-assisted therapy is more effective than manual therapy with inactive placebo in patients with severe PTSD, and that treatment is safe and well tolerated in patients with comorbidities.”
It demonstrates that “they write.” “We conclude that MDMA supportive care is a potentially game-changing therapy that requires immediate clinical testing.”According to this study, MDMA reduces the activity of the amygdala, the fear-processing part of the brain.Fear-related memories have subsided, and there is a release of oxytocin, according to Rick Doblin, author and MAPS founder and executive director, on NBC’s “Today” show on Friday.
The authors go on to say that the study data show the potential benefits of MDMA-assisted therapy for PTSD over the FDA-approved first-line drug therapies sertraline and paroxetine, and that more research is needed. Stated. According to “Today,” the FDA may approve MDMA for PTSD treatment as early as next year.
The current study does have some limitations, including the impact of the COVID-19 pandemic on study size, a lack of racial and ethnic diversity among participants, and the potential for blinding to have expected effects. bottom.Anyone of any age can develop PTSD, and the National Institute of Mental Health (NIMH) reports that roughly half of adults in the United States have experienced at least one traumatic event in their lives.According to the study, the United States “may soon face potentially enormous economic and social consequences of PTSD exacerbated by the COVID-19 pandemic.”
ECSTASY | Don’t forget to follow us on Twitter @njtimesofficial. To get latest updates